{"result": "(\"entity\"<|>KABI GLUTAMINA<|>ORGANIZATION<|>Kabi Glutamina is a brand of glutamine supplement used in nutritional support for patients, particularly in oncology settings.)\n##\n(\"entity\"<|>GLUTAMINA VEGANAT MED<|>ORGANIZATION<|>Glutamina Vegenat Med is a brand of glutamine supplement that is utilized for nutritional support in patients.)\n##\n(\"entity\"<|>RESOURCE GLUTAMINA<|>ORGANIZATION<|>Resource Glutamina is a glutamine supplement brand aimed at providing nutritional support for patients.)\n##\n(\"entity\"<|>GLUTAMINA NM<|>ORGANIZATION<|>Glutamina NM is a brand of glutamine supplement that is used in the context of nutritional support for patients.)\n##\n(\"entity\"<|>NUTRICIÓN ARTIFICIAL<|>EVENT<|>Nutritional artificial refers to the method of providing nutrition to patients who cannot maintain oral intake, often used in oncology settings.)\n##\n(\"entity\"<|>MUCOSITIS<|>EVENT<|>Mucositis is a condition that can occur in oncology patients, characterized by inflammation and ulceration of the mucous membranes, often requiring specific nutritional interventions.)\n##\n(\"relationship\"<|>GLUTAMINA VEGANAT MED<|>NUTRICIÓN EN ONCOLOGÍA<|>Glutamina Vegenat Med is used as a nutritional supplement in oncology to support patients<|>6)\n##\n(\"relationship\"<|>RESOURCE GLUTAMINA<|>NUTRICIÓN EN ONCOLOGÍA<|>Resource Glutamina is utilized in oncology for nutritional support<|>6)\n##\n(\"relationship\"<|>GLUTAMINA NM<|>NUTRICIÓN EN ONCOLOGÍA<|>Glutamina NM is a supplement used in the nutritional management of oncology patients<|>6)\n##\n(\"relationship\"<|>KABI GLUTAMINA<|>NUTRICIÓN EN ONCOLOGÍA<|>Kabi Glutamina is a brand that provides nutritional support for oncology patients<|>6)\n##\n(\"relationship\"<|>MUCOSITIS<|>NUTRICIÓN EN ONCOLOGÍA<|>Mucositis is a condition that necessitates specific nutritional management in oncology<|>7)\n##\n(\"relationship\"<|>NUTRICIÓN ARTIFICIAL<|>NUTRICIÓN EN ONCOLOGÍA<|>Nutritional artificial is a method used to support patients who cannot eat orally, particularly in oncology<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: |\n| HC g | 0 | 3,6 | 0 | 0 |\n| Lípidos | 0 | 0 | 0 | 0 |\n\n## Tabla 7. Módulos de glutamina.\n\n| 100 g | Glutamina Vegenat Med® sobre 5 g | RESOURCE GLUTAMINA® sobres 5 g | GLUTAMINA NM® sobre 10 g | GLUTAMINA NM® vial 5 g/40 ml | Kabi Glutamina® sobre 20 g | Glutamine® sobre 10 g |\n|-------|----------------------------------|--------------------------------|--------------------------|------------------------------|---------------------------|----------------------|\n| KCal | 400 | 400 | 399,5 | 399,5 | 375 | 370 |\n| Prot g | 100 | 100 | 99,7 | 99,7 | 50 | 120 |\n| L glutamina g | 100 | 100 | 99,7 | 99,7 | 100 | 100 |\n| HC g | 0 | 0 | 0,1 | 0 | 40 | 0 |\n| Lípidos | 0 | 0 | 0,09 | 0 | 0 | 0 |\n\ngerida (volumen superior a dos litros cada 24 horas). En las situaciones que cursan con diarrea, es importante evitar la deshidratación y debe suplementarse la dieta con bebidas enriquecidas en fibra soluble sin lactosa. En los casos de mucositis, en los que podemos encontrar, incluso úlceras sobreinfectadas muy doloro-\n\nsas, es necesario iniciar un tratamiento antiálgico y, si es imposible mantener la nutrición oral, se inicia nutrición artificial. Cuando las lesiones mejoran, se inicia una dieta oral líquida o pastosa con alimentos fríos, evitando los alimentos irritantes y ácidos. Sin olvidar que muchos de los episodios de mucositis podrían ha-\n---\n# BLOQUE: NUTRICIÓN EN ONCOLOGÍA\n\nber sido evitados con un tratamiento preventivo vía oral con glutamina.\n\nAnte todos los problemas nutricionales citados deberíamos tener una actitud de prevención antes de que el problema aparezca. Por ejemplo, suprimir los alimentos con alto riesgo bacteriológico en períodos de aplasia, fraccionar la alimentación y potenciar la toma de alimentos hiperenergéticos.\n\nEn estos momentos se abren nuevas expectativas en el soporte nutricional, pudiendo influir en la respuesta no solo variables clásicas como el tipo de tumor, el estadio, la localización y el tratamiento recibido, sino también el genotipo del paciente provocando diferentes respuestas al soporte nutricional en función del genotipo27. En estos pacientes tenemos que seleccionar fórmulas con inmunonutrientes (arginina) que pueden mejorar incluso la estancia media hospitalaria de estos pacientes en 3,5 días5.\n\nDe este modo, las guías ASPEN28 en sus recomendaciones en relación con las fórmulas inmunomoduladoras, indican que se debe utilizar en «pacientes con cirugía en tumores de cabeza y cuello» y las guías ESPEN29 en «pacientes sometidos a cirugía de cáncer de cuello grado A».\n\n## 5. Resumen\n\nEn los pacientes con tumores de cabeza y cuello debemos analizar el estado nutricional antes de la intervención terapéutica (cirugía, radioterapia o quimioterapia), durante el propio tratamiento y tras el tratamiento, para aplicar correctamente los conocimientos actuales en materia de nutrición en pacientes tumorales y mantener un adecuado abordaje de cada patología, utilizando diferentes vías de acceso y fórmulas nutricionales. Sin olvidarnos de una correcta transición a la dieta oral por fases, que en algunas ocasiones puede ser completa a una dieta normal o permanecer el paciente con unas recomendaciones específicas para su disfagia.\n\nDebemos ser capaces de tener herramientas de valoración nutricional precoz para detectar a los pacientes desnutridos con este tipo de tumores, y no olvidarnos que con un grado de recomendación A, debemos utilizar en el soporte nutricional la vía enteral con sustratos inmunomoduladores (arginina) en el perioperatorio independientemente del riesgo nutricional del paciente en un paciente con cáncer de cabeza y cuello que va a ser sometido a laringectomía o faringectomía30. En estos momentos existen interrogantes abiertos, como puede ser la dosis máxima de arginina a administrar por nutrición enteral, demostrando nuestro grupo la superioridad de 19 gramos al día frente a cantidades inferiores31, el efecto sobre la supervivencia de estas fórmulas32 y las ventajas de un adecuado soporte nutricional en estos pacientes no solo en el perioperatorio, sino también en los tratamientos coadyuvantes con quimiorradio-\n\nterapia33. Sin olvidarnos de aspectos que condicionan la situación nutricional como la disgeusia y la xerostomía34.\n\n## 6. Bibli\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>ASPEN<|>ORGANIZATION<|>ASPEN is a professional organization that provides guidelines for nutritional support in patients, particularly those undergoing surgery for head and neck tumors.)\n##\n(\"entity\"<|>ESPEN<|>ORGANIZATION<|>ESPEN is a professional organization that offers recommendations for nutritional support in patients undergoing cancer surgery, specifically for head and neck cancer.)\n##\n(\"entity\"<|>GLUTAMINA<|>EVENT<|>Glutamina is a treatment that can prevent nutritional problems in oncology patients, particularly in those with mucositis.)\n##\n(\"entity\"<|>NUTRICIÓN EN ONCOLOGÍA<|>EVENT<|>Nutritional support in oncology focuses on preventing and managing nutritional issues in cancer patients, especially during treatments like chemotherapy and radiotherapy.)\n##\n(\"entity\"<|>CÁNCER DE CABEZA Y CUELLO<|>EVENT<|>Head and neck cancer refers to a group of cancers that affect the head and neck region, requiring specific nutritional management.)\n##\n(\"entity\"<|>ARGININA<|>EVENT<|>Arginina is an immunonutrient that may improve nutritional support and hospital stay for oncology patients.)\n##\n(\"relationship\"<|>ASPEN<|>ESPEN<|>Both ASPEN and ESPEN provide guidelines and recommendations for nutritional support in oncology patients<|>7)\n##\n(\"relationship\"<|>GLUTAMINA<|>NUTRICIÓN EN ONCOLOGÍA<|>Glutamina is highlighted as a preventive treatment in the context of nutritional support for oncology patients<|>8)\n##\n(\"relationship\"<|>CÁNCER DE CABEZA Y CUELLO<|>NUTRICIÓN EN ONCOLOGÍA<|>Nutritional management is crucial for patients with head and neck cancer<|>9)\n##\n(\"relationship\"<|>ARGININA<|>NUTRICIÓN EN ONCOLOGÍA<|>Arginina is recommended as part of the nutritional support for oncology patients<|>8)\n<|COMPLETE|>"}]}